RingTherapeutics creates small‑molecule drugs that selectively inhibit Ring finger proteins, a novel intracellular target class involved in immune regulation. Their platform combines structure‑based design, high‑throughput screening, and pharmacokinetic optimization to produce oral therapies with improved safety and efficacy for autoimmune and inflammatory diseases.
Funding
$86.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic inflammatory diseases often experience limited treatment options that target specific pathways, leading to suboptimal efficacy and adverse side effects.
Solution
RingTherapeutics develops small-molecule therapeutics that modulate the activity of the Ring finger protein family, a novel class of intracellular targets implicated in immune regulation. By designing selective inhibitors that fine‑tune these pathways, the company aims to provide more precise control over inflammatory responses. Their platform integrates structure‑based drug design, high‑throughput screening, and advanced pharmacokinetic optimization to advance candidates from discovery to clinical evaluation. The approach seeks to deliver oral therapies with improved safety profiles and broader applicability across multiple immune‑mediated conditions.
Target Audience
Primary customers are pharmaceutical partners and biotech companies developing treatments for autoimmune and inflammatory disorders, as well as clinical research organizations conducting early‑phase trials.
Features
- Targeted modulation of Ring finger proteins using proprietary small‑molecule chemistry
- Structure‑guided design pipeline leveraging crystallography and AI‑assisted modeling
- Integrated preclinical platform for rapid assessment of potency, selectivity, and pharmacokinetics
- Oral formulation strategies to enhance bioavailability and patient compliance
- Biomarker‑driven development framework to align therapeutic effects with disease pathways